Stevens-Johnson Syndrome Lawsuit Over Generic Dilantin Use Filed

|
Staff Writers

Add Your Comments

A lawsuit over Stevens-Johnson Syndrome has been filed against Mylan Pharmaceuticals by a Texas man who says that side effects of generic Dilantin caused him to suffer a life-threatening skin reaction. 

The lawsuit was filed by Juan Morales on April 22 in Kanawha Circuit Court in West Virginia. Morales developed Stevens-Johnson Syndrome from generic Dilantin (phenytoin) he was prescribed in April 2008. He was hospitalized at Corpus Christi Medical Center by May 22, 2008, after developing a severe rash that covered most of his body.

Stevens-Johnson Syndrome (SJS) is a severe skin reaction that can occur as a side effect of several medications. It is highly debilitating and causes the skin to burn from the inside out, producing blisters, severe rashes and the skin may begin to separate from the body. When the skin lesions affect more than 30% of the body, the condition is referred to as Toxic Epidermal Necrolysis (TEN). Treatment in a hospital Intensive Care Unit (ICU) or Burn Unit is often required, and the conditions can be fatal in many cases.

Learn More About

Stevens-Johnson Syndrome Lawsuit

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION

Learn More About

Stevens-Johnson Syndrome Lawsuit

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION

Dilantin (phenytoin) is an antiepileptic drug manufactured by Pfizer. Mylan makes a generic version called Phenytek which is considered bioequivalent. In November 2008, the FDA issued a warning that Dilantin and Phenytek carried a risk of Stevens-Johnson Syndrome.

Morales is suing Mylan for failing to warn of the dangers and for selling a defective product. He claims in his lawsuit that had he known there was a risk of Stevens-Johnson Syndrome he would not have taken the medication. He is seeking compensatory and punitive damages of an unspecified amount.

Along with Mylan, the lawsuit lists unknown corporations and several “John Does” as defendants.

Tags: Dilantin, Mylan Pharmaceuticals, Pfizer, Phenytek, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
Image Credit: |

More Stevens-Johnson Syndrome Lawsuit Stories

1 Comments

Laurence
I was not diagnosed with this but I think I may have gotten this shortly after being prescribed phenytoin for having a seizure in July. I had an allergic reaction that caused me to have a series of small red dots on my lower arms. went to the medical clinic from which I was prescribed the meds and they just lowered my dosage by one pill. Three days later my whole entire body was covered in these red dots. I stopped taking those meds shortly after visiting the doctor due to the fact I was getting worst. Now 4 months later I still have some spots on my body with the red dots but they dont effect me now like they did then. Throughout this whole process I have not heard the term stevens-johnson syndrome until I saw a commercial about a lawsuit for dilantin users and researched it a little bit and seen similarities in what I had.

This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

The ‘Can’t Feel My Feet’ Symptom Doctors See in Nitrous Oxide Nerve Injury
Nitrous oxide injury lawsuits are emerging as medical evidence links recreational use of the gas to nerve damage that can cause numbness, balance problems and difficulty walking, often without adequate side effect warnings.
Bard PowerPort Infection Lawsuit Set for Trial To Begin April 21, 2026
A federal judge has scheduled a series of Bard PowerPort trials between April 2026 and February 2027, which will focus on allegations that defective design flaws made the devices susceptible to infections, fractures and migration.
Depo-Provera Lawyers Intending To Remain in MDL Leadership Must Seek Reappointment Judge
A federal judge is calling for dozens of attorneys to reapply for leadership positions in Depo-Provera brain tumor litigation before their appointments expire in March.